Table III.
Drug-metabolism genotypes in African-American breast cancer cases and controls.
| Genes | Genotype | Controls | Cases |
|---|---|---|---|
| GSTM1 | Wild-type | 59 | 37 |
| Null | 28 | 19 | |
| OR (95% CI)a | 1.35 (0.57–3.15) | ||
| P-valueb | 0.828 | ||
| GSTT1 | Wild-type | 71 | 41 |
| Null | 16 | 15 | |
| OR (95% CI)a | 2.37 (0.86–6.55) | ||
| P-valueb | 0.234 | ||
| GSTP1 | II | 25 | 14 |
| I105V | IV | 39 | 29 |
| VV | 13 | 13 | |
| IV vs. II OR (95% CI)a | 1.01 (0.39–2.67) | ||
| VV vs. II OR (95% CI)a | 1.74 (0.48–6.26) | ||
| IV/VV vs. II OR (95% CI)a | 1.14 (0.45–2.90) | ||
| VV vs. II/IV OR (95% CI)a | 1.72 (0.57–5.18) | ||
| P-valueb | 0.525 | ||
| GSTP1 | AA | 70 | 49 |
| A114V | AV | 4 | 5 |
| VV | - | - | |
| AV vs. AA OR (95% CI)a | 1.48 (0.33–6.65) | ||
| VV vs. AA OR (95% CI)a | - | ||
| AV/VV vs. AA OR (95% CI)a | 1.48 (0.33–6.65) | ||
| VV vs. AA/AV OR (95% CI)a | - | ||
| P-valueb | 0.492 | ||
| CYP1B1 | AA | 17 | 19 |
| A119S | AS | 41 | 21 |
| SS | 19 | 15 | |
| AS vs. AA OR (95% CI)a | 0.51 (0.18–1.45) | ||
| SS vs. AA OR (95% CI)a | 0.57 (0.18–1.79) | ||
| AS/SS vs. AA OR (95% CI)a | 0.53 (0.20–1.40) | ||
| SS vs. AA/AS OR (95% CI)a | 0.88 (0.35–2.22) | ||
| P-valueb | 0.177 | ||
| CYP1B1 | LL | 6 | 1 |
| L432V | LV | 28 | 23 |
| VV | 43 | 28 | |
| LV vs. LL OR (95% CI)a | 6.96 (0.58–83.48) | ||
| VV vs. LL OR (95% CI)a | 4.88 (0.43–55.87) | ||
| LV/VV vs. LL OR (95% CI)a | 5.52 (0.50–61.37) | ||
| VV vs. LL/LV OR (95% CI)a | 0.87 (0.38–1.99) | ||
| P-valueb | 0.316 |
a
Odds ratio (OR) adjusted for age, family history, smoking history, age at menarche, age at first live birth and body mass index using logistic regression.
b
Chi-square or Fisher's exact test for genotype distributions.